Lipoprotein(a) epidemiology and role in secondary and primary-and-a-half cardiovascular prevention: From subclinical atherosclerosis to coronary events
American Journal of Preventive Cardiology · 2026-02 · 25 · 101416
DOI: 10.1016/j.ajpc.2026.101416 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Preventive Cardiology, 2026-02. Verfasst von Mateo Iwanowski und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hospital del Mar y Hospital del Mar Research Institute, Barcelona, Spain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk.
Abstract (Originalsprache)
Introduction
Lipoprotein(a) (Lp[a]) is an independent risk factor for atherosclerotic cardiovascular events and aortic stenosis. In Spain, the prevalence of elevated Lp(a) and its clinical impact remain poorly defined.
Methods
We conducted a cross-sectional study including two cohorts: patients discharged after a non-fatal acute coronary syndrome (secondary prevention), and asymptomatic patients with subclinical atherosclerosis ("1.5 prevention"). The prevalence of elevated Lp(a) levels was assessed in both groups. Associations with multivessel coronary artery disease (secondary prevention) and with a coronary artery calcium (CAC) score ≥300 AU (1.5 prevention) were analyzed.
Results
A total of 1043 patients were included (788 secondary prevention). Median Lp(a) levels were 61 nmol/L in secondary prevention and 29 nmol/L in the 1.5 prevention cohort. In secondary prevention, 36.8%, 33.6%, 29.2%, and 24.5% had Lp(a) ≥125, ≥150, ≥175, and ≥ 200nmol/L, respectively; in the 1.5 prevention cohort the corresponding proportions were 27.5%, 24.3%, 17.6%, and 14.1%. In secondary prevention, Lp(a) ≥175 nmol/L was associated with multivessel disease after multivariable adjustment for age, sex, LDLc, and statin treatment (OR 1.45, 95% CI: 1.04-2.01; p = 0.027). In 1.5 prevention, Lp(a) ≥175 nmol/L showed a prevalence of CAC ≥300 AU of 86%. Elevated Lp(a) (≥175 nmol/L) was associated with CAC ≥300 AU (OR 4.47, 95% CI 1.39-20.07; p = 0.023), although this association lost significance after multivariable adjustment.
Conclusions
Elevated Lp(a) levels are common in both populations and correlate with greater atherosclerotic burden. These findings support the systematic assessment of Lp(a) to guide preventive strategies across both patient populations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hospital del Mar y Hospital del Mar Research Institute, Barcelona, Spain.
- Universitat Pompeu Fabra, Barcelona, Spain.
Förderung
- Novo Nordisk
Zitieren
APA
Iwanowski, M., Ruiz-Bustillo, S., Vime-Jubany, J., Zuccarino, F., Zerpa, D. Á. P., Jimenez-Mayorga, L., Rodriguez, S., Rodriguez, N., Cabero, P., Ivern, C., Neus, B. M., Vaquerizo-Montilla, B., & Cainzos-Achirica, M. (2026). Lipoprotein(a) epidemiology and role in secondary and primary-and-a-half cardiovascular prevention: From subclinical atherosclerosis to coronary events. American Journal of Preventive Cardiology, 25, 101416. https://doi.org/10.1016/j.ajpc.2026.101416
Vancouver
Iwanowski M, Ruiz-Bustillo S, Vime-Jubany J, Zuccarino F, Zerpa DÁP, Jimenez-Mayorga L, et al. Lipoprotein(a) epidemiology and role in secondary and primary-and-a-half cardiovascular prevention: From subclinical atherosclerosis to coronary events. American Journal of Preventive Cardiology. 2026;25:101416. doi:10.1016/j.ajpc.2026.101416
BibTeX
@article{Iwanowski2026,
author = {Iwanowski, Mateo and Ruiz-Bustillo, Sonia and Vime-Jubany, Joan and Zuccarino, Flavio and Zerpa, Diego Álvaro Perez and Jimenez-Mayorga, Laura and Rodriguez, Sara and Rodriguez, Nuria and Cabero, Paula and Ivern, Consol and Neus, Badosa Marce and Vaquerizo-Montilla, Beatriz and Cainzos-Achirica, Miguel},
title = {Lipoprotein(a) epidemiology and role in secondary and primary-and-a-half cardiovascular prevention: From subclinical atherosclerosis to coronary events},
journal = {American Journal of Preventive Cardiology},
year = {2026},
volume = {25},
pages = {101416},
doi = {10.1016/j.ajpc.2026.101416}
}
EUVIMED